



Essai Clinique

Généré le 27 avr. 2024 à partir de

Titre	COV-IMMUNO : Essai de phase III avec répartition aléatoire visant à comparer l'immunisation avec IMM-101 à l'observation pour la prévention des infections respiratoires graves et autres infections graves liées à la COVID-19 chez des patients atteints de cancer présentant un risque accru d'exposition
Protocole ID	COV-IMMUNO (IC8)
ClinicalTrials.gov ID	NCT04442048
Type(s) de cancer	Autre
Phase	Phase III
Type étude	Prévention
Médicament	IMM-101
Institution	CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
Ville	
Investigateur principal	Dr David Roberge
Coordonnateur	Mom Phat 514-890-8000 poste 11171
Statut	Fermé
But étude	The purpose of this study is to find out if immunization with IMM-101 will reduce the incidence of severe respiratory and COVID-19 infections in cancer patients. There is currently no vaccination available for COVID-19. However, there are vaccinations for the seasonal flu and pneumonia. IMM-101 is a new type of immune stimulating therapy being developed for the treatment of cancer that may also help in preventing severe respiratory and COVID-19 infections. Laboratory tests show that IMM-101 works by activating parts of the immune system that are also involved with protecting against viral and bacterial infections, so that if you are exposed to these types of infections your body may be able fight off the infection better. That could help prevent severe symptoms from respiratory and COVID-19 related infections. It has been studied in over 300 cancer patients who have also been receiving other cancer treatments, including chemotherapy and radiation, and seems promising, but it is not clear if it can offer better results than not having the immunization at all.
Critères d'éligibilité	
Critères d'exclusion	